Obesity trials in Japan

In Japan 36 Also abroad 1940

36 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Where
Aichi, Fukuoka, Hokkaido, Osaka, Tokyo
Age
18 years and over
People
2,000 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07351045 · EU 2025-523104-71-00
Phase 3Taking people
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Where
Aichi, Fukuoka, Hokkaido, Osaka, Tokyo
Age
18 years and over
People
1,600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07351058 · EU 2025-523106-32-00
Phase 3Taking people
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
Where
Chūōku, Ichinomiya-shi, Izunokuni-shi, Kamakura-shi, Kawagoe-shi, Kitakyushu-shi, Kyoto, Mito, Nishinomiya-shi, Ōmihachiman, Yokohama
Age
18 years and over
People
500 worldwide
Run by
AstraZeneca
See details and how to joinNCT07776509 · EU 2025-523295-23-00
Phase 3Taking people
A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)
Where
Amagasaki, Chiyoda-ku, Chuo-ku, Fukuoka, Hachiōji, Hachioji-shi, Kasuya-gun, Matsuyama, Mihama-ku, Minato-ku, Minoh, Mito, Naka, Nerima-ku, Osaka-shi Ikuno-ku, Sapporo, Shinjuku-ku, Soka-shi, Suita, Takamatsu, Tokyo, Toshima-ku, Toyonaka-shi, Yokohama
Age
18 years and over
People
197
Run by
Pfizer
See details and how to joinNCT07794774
Phase 3Taking people
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
Where
Chuo-ku, Shinjuku-ku, Suita
Age
18 years and over
People
954 worldwide
Run by
Pfizer
See details and how to joinNCT07595549 · EU 2026-525318-75-00
Phase 3Taking people
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Where
Chūōku, Suita-shi, Tsuchiura
Age
18 years and over
People
2,001 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07794579 · EU 2026-526175-35-00
Phase 3Taking people
A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)
Where
Amagasaki, Chiyoda-ku, Chuo-ku, Fukuoka, Hachiōji, Hachioji-shi, Kasuya-gun, Matsuyama, Mihama-ku, Minato-ku, Minoh, Mito, Naka, Nerima-ku, Osaka-shi Ikuno-ku, Sapporo, Shinjuku-ku, Soka-shi, Suita, Takamatsu, Tokyo, Toshima-ku, Toyonaka-shi, Yokohama
Age
18 years and over
People
180
Run by
Pfizer
See details and how to joinNCT07794761
Phase 3Not yet taking people in Japan
A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
Where
Arakawa-ku, Tokyo, Okayama, Sendai-shi, Miyagi, Tokyo, Yamato-shi
Age
18 years and over
People
1,408 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT07919405
Phase 3Taking people
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Where
Iruma-gun, Isesaki-shi, Kyoto, Meguro-Ku, Moriyama, Nara, Osaka, Saga, Zentsujichó
Age
6 years to 17 years
People
125 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06672549
Phase 3Taking people
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
Where
Iruma-gun, Isesaki-shi, Kawaramachidori, Kamigyo-ku, Kyoto-city, Meguro-Ku, Moriyama, Nara, Osaka, Saga, Zentsujichó
Age
12 years to 17 years
People
150 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06672939 · EU 2024-514081-40-00
Phase 3Taking people
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
Where
Arakawa City, Chiba, Chiyoda City, Chūōku, Higashiibaraki, Kitakyushu, Matsudo, Minatoku, Nagoya, Naka-ku, Yokohama-Shi, Narashino, Nonoichi, Okayama, Osaka, Ōta-ku, Saitama-shi, Sendai, tabashi City, Toride, Tsukuba
Age
18 years and over
People
1,000 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07202884 · EU 2025-522514-23-00
Phase 3Taking people
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Where
Chigasaki, Chūōku, Kamakura, Kasuya-gun, Kawaguchi, Kita-ku, Mihama-ku,Chiba City, Naha, Oyama, Setagaya-ku, Sōka, Tsuchiura, Ushiku, Yokohama
Age
18 years and over
People
1,035 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07282600 · EU 2025-523658-15-00
Phase 3Taking people
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Where
Chiba, Chūōku, Kitakyushu-Shi, Miyazaki, Nagareyama, Ōita, Saitama, Sashima, Sendai, Shinagawa-ku Tokyo, Suginami City, Toyohashi, Yamagata
Age
18 years and over
People
900 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07353931 · EU 2025-523768-19-00
Phase 3Taking people
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Where
Bunkyō City, Fukuoka, Kitahiroshima, Kitakyushu, Minatoku, Osaka, Sapporo, Shibuya-ku, Urasoe, Yokohama
Age
18 years and over
People
800 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07369011 · EU 2025-523769-11-00
Phase 3Taking people
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Where
Chūōku, Izumisano, Kawasaki, Kisarazu, Kure, Kyoto, Matsuyama, Osaka, Sapporo, Shimonoseki, Wakayama
Age
18 years and over
People
900 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07392190 · EU 2025-523659-73-00
Phase 3Taking people
A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Where
Chūōku, Narashino, Sōka, Tsuchiura
Age
18 years and over
People
1,000 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07881458 · EU 2026-527230-31-00
Phase 2Taking people
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
Where
Hachiōji, Kamakura-shi, Naka, Narita
Age
18 years and over
People
120 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07783802
Phase 3Not yet taking people in Japan
A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
Where
Chiyoda City, Chūōku, Kawasaki, Kin-cho, Kunigami-gun, Nerima-ku, Shinjuku, Shinjuku-ku, Urasoe
Age
18 years and over
People
2,115 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07881432 · EU 2026-526047-34-00
Phase 3Not yet taking people in Japan
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
Where
Hamadayama, Suginami-ku, Himeji, Kisarazu, Kōriyama, Kumamoto, Kurume, Osaka, Shinjyuku, Uji
Age
45 years to 64 years
People
3,000 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07900633 · EU 2026-525919-14-00
Phase 3Taking people
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
Where
Chūōku, Fukuoka, Hachioji-shi, Osaka, Shibuya-ku, Takatsuki-shi
Age
18 years and over
People
2,500 worldwide
Run by
AstraZeneca
See details and how to joinNCT07784725 · EU 2025-523379-41-00
Phase 3Taking people
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Where
Chiba, Fujinomiya-shi, Fukuoka, Hachioji-shi, Hamamatsu, Higashiyamato-shi, Himeji-Shi, Kagoshima, Kanazawa, Kitaazumi-gun, Kitakyushu-shi, Kumamoto, Kyoto, Niigata, Ōita, Sagamihara-shi, Sapporo, Shinagawa-ku, Suginami-ku, Suita-shi, Takamatsu, Takarazuka-shi, Toyoake-shi, Yonago-shi
Age
18 years to 99 years
People
5,056 worldwide
Run by
Amgen
See details and how to joinNCT07037459
Phase 3Taking people
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
Where
Aira, Chūōku, Fukuoka, Hachioji-shi, Izunokuni-shi, Kumamoto, Nagoya, Nerima-ku, Osaka, Saga, Sapporo, Shinjuku-ku, Suita-shi, Tanabe-shi
Age
18 years and over
People
1,500 worldwide
Run by
AstraZeneca
See details and how to joinNCT07784270
No phaseTaking people
Cities for Better Health Childhood Obesity Prevention Initiative in JAPAN
Where
Chiba
Age
6 years to 12 years
People
2,200
Run by
Chiba University
See details and how to joinNCT07061665
Phase 3Taking people
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
Where
Amagasaki-shi, Chūōku, Kasugai-shi, Koga-shi, Maebashi, Minatoku, Naka, Shinjuku-ku, Shizuoka, Suita-shi, Toshima-ku, Yamato-shi, Yokohama
Age
18 years and over
People
4,500 worldwide
Run by
AstraZeneca
See details and how to joinNCT07667803
Phase 3Taking people
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
Where
Fukuoka, Hiroshima, Kumamoto, Okinawa, Osaka, Sapporo-shi, Hokkaido, Shizuoka, Tokyo
Age
18 years and over
People
300 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT07571109 · EU 2024-520443-16-00